Major Depressive Disorder

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.

There was also a decline depression care in recent years among adolescents and young adults.

There could be a lasting impact caused by some of the changes due to the pandemic.

This edition from the 10 Year Plan features perspective from leadership at APA and AADPRT, as well as survey results from psychiatrists.

For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.

J. John Mann, MD, discusses potential next steps for further assessment of ketamine's antidepressant effects.

J. John Mann, MD, discusses findings in a new study that uncovers the mechanisms behind Ketamine's antidepressant effect.

J. John Mann, MD, compares esketamine nasal spray to intravenous administration and explains the drawbacks of the newly approved treatment method for MDD.

The majority of older adults participating in the study expressed outrage at what they deemed to be an inadequate government response to the pandemic.

J. John Mann, MD, gives a brief overview of where we are now in treatment of major depressive disorder.

Low- and moderate-frequency magnetic seizure therapy help patients with treatment-resistant depression go into remission.

A number of new modifiable risk factors for depression were identified including confiding in others, time spent watching television, and daytime napping.

According to new findings, low Glx response is associated with increase in clinical improvements in at-need patients.

The risk of depression or clinically relevant depressive symptoms did not significantly differ between a group taking Vitamin D and a group taking a placebo.

MagVenture TMS Therapy can be used as adjunctive therapy to other OCD treatments.

A leading psychiatric expert discusses some of the pitfalls people face due to the ongoing pandemic.

Approximately half of depression patients do not sufficiently benefit after treated with electroconvulsive therapy, leading to high rates of relapses.

The level of distress for adults in the UK rose from 18.9% in 2018-19 to 27.3% in April.

The fast-acting therapy has been long-discussed for its unique benefits to severe patients—as well as notable concerns surrounding its administration.

Impairment in reward-processing subcomponent categories is associated with tasks assessing option valuation, reward bias, and reinforcement learning.

The findings demonstrate the importance of providers to manage diabetes, diabetic retinopathy, and mental illness comorbidities.

Patients with bipolar depression have struggled during the COVID-19 pandemic.

Fluoxetine alone was more effective treating depression than a combination of fluoxetine with cognitive behavioral therapy.

Investigators identify the extent to which a machine-learning approach predicts acute improvement for individual depressive symptoms with antidepressants based on pre-treatment symptom scores and EEG measures.

Many tools are becoming available to psychiatrists who need to strengthen their reach of care outside the office.